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Introduction
HLA (also known as the MHC in other vertebrates) proteins present 
self- and non-self peptides to the T cell receptor (TCR) to maintain 
self-tolerance and adapted immunity (ref. 1 and Figure 1A). Cer-
tain HLA-DR-DQ haplotypes, such as DR3-DQA1*05-DQB1*02:01 
(DR3-DQ2.5) and DR4-DQA1*03-DQB1*03:02 (DR4-DQ8.3) in 
Europeans, confer a risk for autoimmune diseases, including type 
1 diabetes (T1D), celiac disease, and autoimmune endocrinopa-
thy (2–7). In East Asian populations (Japanese) DR9-DQA1*03-
DQB1*03:03 (DR9-DQ9.3) and DR4-DQA1*03-DQB1*04:01 
(DR4-DQ4.3) are the major risk factors for T1D (8–10) and other 
autoimmune endocrinopathies (11) (Table 1 and see Supplemen-
tal Figure 1 for abbreviations for the DQA1-DQB1 haplotypes [DQ 
haplotype];; supplemental material available online with this 
article; doi:10.1172/JCI74961DS1). Despite accumulating genetic 
evidence, the mechanism through which particular HLA alleles 
confer risk for autoimmune diseases has not been fully uncovered.
The HLA-autoimmunity association has been generally 
explained by the allelic differences in self-epitope presentation 
(see, for instance, refs. 12, 13). However, the binding affinity and 
specificity in the MHC-self-epitope interaction are highly vari-
able. Studies of T1D, multiple sclerosis, and other autoimmune 
disorders have found that the disease-relevant self-epitopes 
interact with the MHC with high or low affinity or in kinetically 
unfavorable registers (14–29). Some of these self-epitopes bind 
to both the disease risk and neutral/protective allele products 
(i.e., promiscuous binders) (15, 30–32). Although self-epitope 
presentation is critical in autoimmune pathogenesis, the above 
findings suggest that additional factors may also contribute to the 
allele-specific disease risk.
In the 1990s, Kwok’s and Unanue’s groups and other research-
ers reported that the T1D risk alleles of HLA-DQ and murine I-A 
encode SDS unstable proteins (33–36). The SDS stability measures 
the migration of non-boiled MHC class II (MHC II) on SDS-PAGE 
(37) and was initially regarded as an indicator of peptide occu-
pancy. It was later found that SDS stability reflects the stabiliza-
tion of the peptide-MHC (pMHC) at the P1 and P9 pockets and 
at the extended peptide residues (38–45). In some of these and 
other studies, however, SDS stability was not affected by the pep-
tide-binding affinity (41, 42, 46) and was maintained through the 
peptide-independent stabilization (46). The mechanism of SDS 
stability, and hence its relevance to the MHC protein function, has 
remained controversial.
The stability of the pMHC is maintained through the het-
erodimerization of the α and β subunits and peptide presen-
tation (Supplemental Figure 2). The interaction of the peptide 
side chain atoms with MHC stabilizes the pMHC in a pep-
tide-specific manner and has been extensively analyzed (1). In 
this study, we focused on the possibilities that the MHC sta-
bility might differ intrinsically among the alleles and that this 
stability may be associated with autoimmunity. The intrinsic 
stability of the MHC protein in this study refers to the MHC 
stability that is formed through the α/β assembly and peptide 
main chain interactions. The contribution of both the polymor-
phic and nonpolymorphic residues in the heterodimerization 
and peptide main chain interactions suggests that MHC stabil-
ity might differ intrinsically among alleles. However, it has not 
been possible to measure the intrinsic stability of MHC protein 
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MHC protein. ΔMHC was then used to analyze the relationship 
between the intrinsic stability of MHC protein and autoimmune 
disease risk. ΔMHC measures the combined outcomes of the 
heterodimer assembly, cell-surface transport, and turnover, 
but not the chemical or physical stability of the MHC protein. 
However, for simplicity, ΔMHC is used as an equivalent to the 
protein stability in this article.
In this study, we identified an allelic diversity in the intrinsic 
stability of HLA-DQ that has been maintained through evolution 
and is associated with genetic risk for T1D. Our study provides a 
new framework through which to interpret the HLA-autoimmunity 
association profiles and uncover the mechanism of autoimmunity.
or to demonstrate its allelic differences, because the pMHC is 
usually stabilized through both the peptide main chain and side 
chain interactions.
To detect the potential allelic differences in the intrinsic sta-
bility of the MHC protein, we used an alternative approach to 
the conventional stability assays. Specifically, instead of analyz-
ing protein stability itself, we measured the biological outcome, 
the cell-surface expression of MHC protein. We quantified the 
amount of cell-surface MHC in engineered conditions and con-
firmed, through the use of mutagenesis and the model peptides, 
that the level of cell-surface MHC protein density (referred 
to herein as the ΔMHC) reflects the intrinsic stability of the 
Figure 1. Measurement of ΔMHC. (A) Structure of MHC II (DQ0602 [pdb: 1uvq]) (70). MHC II is a heterodimeric transmembrane glycoprotein that is composed 
of one α and one β subunit. The α1 and β1 domains constitute the peptide-binding groove, and the α2 and β2 domains form the constant domain. In the case of 
HLA-DQ, HLA-DQA1 and -DQB1 encode the α and β subunits, respectively. (B) Outline of the ΔMHC assay. The ΔMHC assay measures cell-surface MHC expres-
sion levels normalized to the internal control GFP. The HLA-DQB1–stable cells (i) were transduced with the retroviral vector pMXs-IG/DQA1 (52) (ii).  
HLA-DQ was expressed on the cell surface in the presence of both the HLA-DQA1 and -DQB1. Cell-surface HLA-DQ expression and cytosolic GFP expression 
were measured by flow cytometry (iii). (C) Representative data from the ΔMHC assay for DQ0602 (left panels) and DQ2.5 (right panels). To quantify cell-surface 
MHC expression, the HLA-DQB1–stable cell line was transduced with a graded concentration of retrovirus containing pMXs-IG/DQA1. Expression levels of both 
HLA-DQ and GFP increased with the concentration of the retrovirus. Numbers indicate the MFI for GFP-negative and -positive cells and for the isotype control 
and anti–HLA II β (WR18). Dashed lines indicate the highest MFI in each sample set. GFP (green), anti–HLA II β (WR18) (magenta), and isotype control (black). 
(D) The increase in cell-surface MHC expression relative to GFP (ΔMHC) was calculated by plotting the MFI (GFP) and MFI (MHC) (Supplemental Figure 3A). The 
ΔMHC for each HLA-DQ allelic pair was normalized to the ΔMHC of DQ0602, which was measured on the same day. The ΔMHC for DQ2.5 and its normalized 
value are shown. See also Supplemental Figures 3–5 and Methods.
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imize interassay variation, ΔMHC was normalized to 
ΔMHC for the DQA1*01:02-DQB1*06:02 haplotype 
product (DQ0602), which is highly SDS stable (36) 
and showed one of the highest ΔMHC values among 
the tested alleles. Hereafter, the ΔMHC values that 
were normalized to the ΔMHC of DQ0602 are indi-
cated in the figures unless otherwise specified. Repre-
sentative ΔMHC assay data are presented in Supple-
mental Figure 4, A and B. ΔMHC was measured for 
the major HLA-DQ alleles in worldwide populations 
and in their possible trans combinations, given that 
the trans DQA1-DQB1 pair forms heterodimers (54), 
and certain trans combinations are associated with 
autoimmunity (55–59). In this study, the HLA allele 
and haplotype protein products are indicated using 
the nonitalic version of the gene name (e.g., DQ0602 
represents the DQ0602 haplotype product).
Figure 2A shows the ΔMHC profile for HLA-DQ. 
ΔMHC varied by nearly 100-fold among the HLA-DQ 
alleles. Consistent with earlier work (60–62), HLA-
DQA1 and DQB1 alleles of the same evolutional sub-
lineage (63) expressed HLA-DQ on the cell surface 
(Figure 2, A and B). These sublineages are referred to 
herein as the subgroups DQ2/3/4 and DQ5/6. HLA-
DQA1*02, *03, and *05 and certain DQB1*06 alleles 
also expressed HLA-DQ on the cell surface (Figure 
2A). HLA-DQ cell-surface expression was not detect-
able in the absence of HLA-DQA1 or in the presence 
of the incompatible HLA-DQA1 alleles (Supplemental 
Figure 5, A–C, and Supplemental Table 1). The HLA-DQ cell-sur-
face expression pattern and the assembly of the DQα and DQβ 
subunits were confirmed using stable insect cells (Drosophila 
melanogaster S2) (Supplemental Figure 6, A–D).
Among the major DQ haplotypes, DQ0602 and DQ9.2 showed 
the highest ΔMHC, whereas the ΔMHC of the DQA1*01:04-
DQB1*05:01 (DQ0501) product was below the threshold (Figure 
2, A and C, and Supplemental Table 1). The conserved hierarchy in 
ΔMHC among the DQ5/6 (DQA1*01:02 > *01:01, *01:03 > *01:04 
and DQB1*06:02 > *06:01, *06:03 > *06:04 > *05:03 > *05:02 > 
*05:01) (Figure 2A and Supplemental Figure 7, A–D) indicates that 
polymorphic variants in each subunit act independently of the vari-
ants in the other subunit in the regulation of ΔMHC. In DQ2/3/4, 
ΔMHC decreased in the order of DQA1*02 > *03, *05 > *04 > *06 
and DQB1*03:01, *03:03, *04 > *02, *03:02, except for the high 
ΔMHC value of DQA1*03-DQB1*02 (DQ2.3) (Figure 2A and Sup-
plemental Figure 7, E–H). The mechanism that stabilizes DQ2.3 was 
not identified in this study. The hierarchy in ΔMHC for the major 
DQ haplotype products was similar to the hierarchy in the SDS sta-
bility (DQ0602 > DQ0603 > DQ0604, DQ7.3, DQ0501, DQ8.3, 
DQ2.5) that was measured using the cell lysates of DQ-homologous 
B lymphoblastoid cell lines (B-LCLs) (36). SDS stability may be sen-
sitive to the variants at 57β, given that DQ9.3 (ΔMHC = 0.12, carries 
Asp57β) is SDS stable (43), whereas DQ2.2 (ΔMHC = 0.4–0.6, car-
ries non-Asp57β) is reported as SDS unstable (43).
The mAb WR18 stains diverse HLA-DQ (64, 65), -DR, and -DP 
allele products (H. Miyadera, unpublished observations), indicat-
ing that the mAb WR18 recognizes a common epitope on HLA II β. 
Results
Measurement of ΔMHC. We generated an MHC expression sys-
tem using fibroblasts (NIH3T3, murine embryonic fibroblasts) 
as expression hosts and GFP as an internal control. MHC II is 
expressed in a functionally intact form in fibroblasts (47, 48) but 
in inappropriately paired or unassembled forms, the α and β sub-
units are retained during intracellular transport and are degraded 
(49, 50). The observation that cell-surface MHC expression on 
fibroblasts is altered through the gain and loss of hydrogen bond(s) 
(H-bond) between the MHC and the peptide (51) indicates that 
subtle changes in the net stability of the pMHC can be detected 
using cell-surface MHC protein expression levels. H2-DM, which 
is expressed in antigen-presenting cells (APCs) and stabilizes 
pMHC, may be absent in this expression system.
We established HLA-DQB1–stable cells using the retrovirus 
vector pMXs-puro and the packaging cell line PLAT-E (52, 53). We 
then transduced the HLA-DQB1–stable cells with a retrovirus con-
taining pMXs-IG/DQA1 (Figure 1B). Using a graded concentration 
of retrovirus particles, it was possible to express both the HLA-DQ 
and GFP at several different levels (Figure 1C). Cell-surface HLA-
DQ and cytosolic GFP were measured by flow cytometry using 
the pan–HLA II β mAb (WR18). The mean fluorescence intensity 
(MFI) for both the MHC [MFI (MHC)] and the GFP [MFI (GFP)] 
showed good linear correlation (R2 >0.9). The increase in MFI 
(MHC) relative to MFI (GFP) (slope in Figure 1D), which indicates 
the amount of cell-surface MHC normalized to GFP, was calcu-
lated for each HLA-DQ allelic pair and was designated as ΔMHC 
(Figure 1, C and D, and Supplemental Figure 3, A and B). To min-
Table 1. Associations of DR-DQ haplotypes with autoimmune and other 
immune disorders
DR-DQA1-DQB1 haplotype Susceptible Protective
DR3-DQ2.5 (DRB1*03-DQA1*05-DQB1*02)A APS type II
Celiac disease
Selective IgA deficiency
MS
SLE
T1D
DR4-DQ8.3 (DRB1*04-DQA1*03-DQB1*03:02)A APS type II
Celiac disease
T1D
DR9-DQ9.3 (DRB1*09-DQA1*03-DQB1*03:03)B APS type III
T1D
Microscopic polyangiitis
DR4-DQ4.3 (DRB1*04-DQA1*03-DQB1*04:01)B APS type III
T1D
DR15-DQ0602 (DRB1*15-DQA1*01:02-DQB1*06:02) Narcolepsy APS types II and III
MS Selective IgA deficiency
SLE T1D
AHaplotypes commonly observed in Europeans. BHaplotypes commonly observed in the 
Japanese population. APS type II (6); celiac disease (56, 137); selective IgA deficiency 
(5, 138); MS (4, 5, 139); SLE (4, 5); T1D (Europeans) (59, 79, 80); APS type III (11); T1D 
(Japanese) (10); microscopic polyangiitis (140); narcolepsy (141). MS, multiple sclerosis; 
SLE, systemic lupus erythematosus. 
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a strong binder of DQ0602 (30), and 1.5-fold in the presence of the 
class II–associated invariant chain peptide (CLIP)81–107 (Figure 3A). 
ΔMHC decreased 0.6-fold in the presence of insulin B9–23, a weak 
binder of DQ0602 (30), as well as in the presence of an artificial 
negative control peptide (GGSGGSGGSGGS) (GGS peptide) (Fig-
ure 3A), with which the interaction of the MHC protein with the 
peptide side chain may be limited. These data confirm that ΔMHC 
reflects the net stability of the pMHC.
The effect of endogenous peptides on the ΔMHC profile (Fig-
ure 2A) was estimated using DQB1-GGS peptide fusion constructs. 
The ΔMHC profile was reproducible with pan-HLA II β mAbs 
BL-IA/6, TDR31.1 (Supplemental Figure 8, A–C), and IVA-12 (H. 
Miyadera, unpublished observations). The ΔMHC assay was not 
successful in the B cell lines due to the low efficiency of retroviral 
transduction (H. Miyadera, unpublished observation).
The effects of peptides on ΔMHC. To confirm that ΔMHC reflects 
the net stability of the MHC protein, ΔMHC was measured in the 
presence of high- and low-affinity peptides using the DQB1*06:02 
peptide fusion constructs (designed according to ref. 66) (see 
Methods). ΔMHC increased 3.4-fold in the presence of insulin B1–15, 
Figure 2. ΔMHC profile for the HLA-DQ allele products. (A) ΔMHC profile for HLA-DQ. Numbers and color scale indicate the ΔMHC (normalized to the ΔMHC of 
DQ0602). ΔMHC values below the threshold (<0.005 after normalization) are blank. Graphs display the ΔMHC value for each subgroup. Error bars represent the 
SEM. See also Supplemental Table 1. (B and C) ΔMHC profiles for the major HLA-DQ allele products (B) and the major DQ haplotype products (C). In C, the DQ 
haplotypes that are present at a haplotype frequency greater than 0.03 in at least 1 of the following populations are magenta colored: Congo Kinshasa Bantu 
(n = 90) (122, 135); Tunisian (n = 100) (122); South Korean (n = 324) (122); Indian Uttar Pradesh (n = 202) (122, 136); and European-American (n = 1,899) (133).
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We analyzed the effect of CLIP on ΔMHC using the DQB1-
CLIP81–107 fusion constructs. The fusion of CLIP81–107 greatly 
increased ΔMHC for certain alleles including DQ2.5 (Figure 3D), 
which is consistent with the high affinity of CLIP94–104 for DQ2.5 
(68). The variable effects of CLIP81–107 on ΔMHC of the tested alle-
les indicate that the ΔMHC profile (Figure 2A) was not affected by 
CLIP-mediated stabilization.
Collectively, the ΔMHC profile (Figure 2A) does not appear to 
be biased by endogenous peptides, invariant chain, or CLIP. These 
observations support the possibility that the ΔMHC profile rep-
resents the allelic hierarchy in intrinsic HLA-DQ protein stability.
Polymorphic residues that regulate the ΔMHC of DQ5/6. We 
next searched for polymorphic sites that regulate ΔMHC. Sup-
plemental Figures 11 and 12 show the pairwise comparisons of 
ΔMHC and the polymorphisms between the representative alle-
les (Supplemental Figure 11, A and B, and Supplemental Figure 
12, A and B). For the highly conserved DQ5/6 subgroup, the 
responsible residues were identified through mutagenesis. For 
the highly polymorphic DQ2/3/4 subgroup, the major regulators 
of ΔMHC were identified through association analysis (see Sup-
plemental Figure 13, A and B, for the amino acid sequence align-
ments of HLA-DQ).
The presence of GGS peptide decreased ΔMHC for nearly all of 
the tested alleles; however, the overall allelic hierarchy in ΔMHC 
was maintained in the presence of the GGS peptide (Figure 3B, 
and Supplemental Figure 9, A and B). These data indicate that 
the HLA-DQ proteins in Figure 2A were loaded with endogenous 
peptides and were not empty heterodimers. The high ΔMHC val-
ues of DQ0602, DQ9.2, and DQ2.2 indicate that these HLA-DQ 
proteins are inherently stable. DQ2.2 showed relatively large inter-
assay variation with and without GGS peptide (Figure 3B). DQ2.3 
showed relatively high ΔMHC values, even in the presence of GGS 
peptide (Supplemental Figure 9B). It is currently unknown whether 
the GGS peptide occupies the peptide-binding groove of HLA-DQ.
MHC II is usually coexpressed with the invariant chain, which 
influences peptide loading and trafficking of the MHC II protein 
(67). To examine whether the lack of the human invariant chain 
affected cell-surface HLA-DQ expression, we measured ΔMHC 
in cells that abundantly expressed the human invariant chain 
(Supplemental Figure 10). In the presence of the human invari-
ant chain, ΔMHC decreased by nearly half, possibly due to insuf-
ficiencies in cathepsins and HLA-DM. We found that the ΔMHC 
hierarchy was maintained in both the presence and absence of the 
human invariant chain (Figure 3C).
Figure 3. The effect of peptides on the ΔMHC. (A) ΔMHC profile for the DQ0602-peptide fusion constructs. HLA-DQA1*01:02–stable cells were transduced 
with pMXs-IG/DQB1*06:02, which carries the peptide sequence between the signal and the mature protein sequence (see Methods). (B) ΔMHC profile in the 
presence and absence of the artificial negative control peptide GGS. HLA-DQA1–stable cells were transduced with pMXs-IG/DQB1 (without peptide fusion) 
(white bars) or with pMXs-IG/DQB1-GGS peptide (black bars). (C) ΔMHC profile for HLA-DQ in the presence (black bars) and absence (white bars) of the 
human invariant chain. ΔMHC was measured in NIH3T3 cells that stably expressed the human invariant chain (Supplemental Figure 10) and HLA-DQA1. (D) 
ΔMHC profile for the DQB1-CLIP81–107 fusion constructs. Error bars represent the SEM (n ≥3).
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Figure 4. Association of 
amino acid variants in 
DQ2/3/4 with ΔMHC. (A) 
The HLA-DQ heterod-
imers in DQ2/3/4 are 
organized in the order of 
their ΔMHC values. Error 
bars represent the SEM. 
(B and C) Polymorphic 
variants in HLA-DQA1 (B) 
and -DQB1 (C) and their 
association with ΔMHC. 
Numbers indicate the 
amino acid residues. 
Residue numbers for the 
α2, β2, transmembrane, 
and cytosolic domains 
are shaded in brown. 
Variants identical to 
DQA1*02:01-DQB1*04:01 
(magenta) and other 
variants (white or gray). 
The association between 
each amino acid variant 
and ΔMHC was analyzed. 
The lowest P values at 
each site are indicated 
on the left with asterisks 
(2-tailed t test). The 
association table is pre-
sented in Supplemental 
Table 2.
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In DQ5/6, the HLA-DQA1*01 alleles differ at Asp/Gly2α, Tyr/
Phe25α, Gln/Glu34α, and Lys/Arg41α. Of these, variants at 2α, 
25α, and 34α, but not at 41α, significantly altered ΔMHC (Supple-
mental Figure 14, A–D). Tyr/Phe25α also altered ΔMHC between 
DQA1*04:01 and *06:01 (Supplemental Figure 14E). Asp2α, which 
is located outside of the peptide-binding groove, stabilized the 
HLA-DQ protein, possibly through the formation of interdomain 
H-bonds (Supplemental Figure 14, F and G). Tyr25α and Gln34α 
stabilized the HLA-DQ through the interdomain/intersubunit 
H-bonds and interactions with the peptide main chain (Supplemen-
tal Figure 14, H and I). The hierarchy in ΔMHC among DQA1*01 
alleles is perfectly explained by the stabilizing and destabilizing 
effects of 2α, 25α, and 34α (Supplemental Figure 14J).
For DQB1*06, we analyzed the effect of polymorphic residue 
on ΔMHC through mutagenesis at the sites that differed between 
DQB1*06:02 and *06:04 (9β, 30β, 57β, 70β, and 87β) (Supplemen-
tal Figure 14, K and L). The replacement of Tyr30β with His30β in 
DQB1*06:02 and of Tyr9β with Phe9β in DQB1*06:04 decreased 
ΔMHC. However, the substitution of Phe9β with Tyr9β in the pres-
ence of Tyr30β (in DQB1*06:02) and the substitution of His30β with 
Tyr30β in the presence of Tyr9β (in DQB1*06:04) did not affect 
ΔMHC (Supplemental Figure 14, K and L), indicating that Tyr9β and 
Tyr30β act complementarily to increase the ΔMHC. Tyr9β forms an 
H-bond with Asn72α, which interacts with the peptide main chain 
(Ser7p O and Glu9p N) in DQ8.3 (ref. 69 and Supplemental Figure 
14M). Tyr30β interacts with the peptide main chain (Ser7p N) in 
DQ8.3 (ref. 69 and Supplemental Figure 14N). The higher ΔMHC of 
DQB1*06:02 compared with that of DQB1*06:03 suggests a greater 
stabilizing effect of Phe9β-Tyr30β than of Tyr9β-His30β (Supple-
mental Figure 11B). Asp57β mediates an H-bond/salt bridge with 
Arg79α and H-bonds with Ala10p N and Tyr37β (ref. 70 and Supple-
mental Figure 14O). Arg70β, which is predicted to interact with the 
p6 residue (71), increased ΔMHC relative to Gly70β in DQB1*06:04, 
but not in DQB1*06:02 (Supplemental Figure 14, K and L). Tyr/
Phe87β did not affect ΔMHC (Supplemental Figure 14, K and L). Col-
lectively, the hierarchy in ΔMHC among DQB1*06:02, *06:03, and 
*06:04 is shaped mainly through the variants at 9β, 30β, and 57β, the 
residues that alter the intrinsic stability of the MHC protein.
The large difference in ΔMHC between DQB1*05 and *06 is 
consistent with their difference in SDS stability (36) and was repli-
cated with pan–HLA II β mAb IVA-12 and the DQw1-specific mAb 
Genox3.53 (H. Miyadera, unpublished observations). We deter-
mined that 14β (Leu in DQB1*05 and Met in DQB1*06), which 
projects its side chain toward the interface of the α1 and α2/β2 
domains, is one of the responsible variants that diversifies ΔMHC 
between DQB1*05 and *06 (H. Miyadera, unpublished observa-
tions). Other variants that also contribute to the low ΔMHC value 
of DQB1*05 have not been fully elucidated in this study.
Polymorphic residues that regulate the ΔMHC of DQ2/3/4. To 
identify the residues that affect the ΔMHC value of DQ2/3/4, we 
conducted an association analysis between each amino acid vari-
ant and ΔMHC (Figure 4, A–C). In HLA-DQA1, variants at 47α 
Figure 5. Stabilization/destabilization of HLA-DQ protein by 47α and 57β. (A) The location of Arg47α (magenta) in the protein structure of DQ0602 (PDB: 
1uvq) (70). α1 domain (white), α2 domain (pink), and bound peptide (yellow). (B–D) Interdomain H-bonds formed between the α1 and α2/β2 domains in the 
presence of Arg47α in DQA1*01:02 (DQ0602) (PDB: 1uvq) (70) (B), Gln47α in DQA1*03 (DQ8.3) (PDB: 2nna) (69) (C), and Cys47α in DQA1*05 (DQ2.5) (PDB: 
1s9v) (72) (D). α1 and α2 domains (magenta in B, orange in C, and pink in D); β2 domains (gray); water molecules (red spheres); and distances of less than 3.4 
Å (green dots). (E) Effects of variants at 47α on the ΔMHC values of DQ2.5 and DQ8.3. (F) Effects of variants at 47α on the ΔMHC values of DQA1*06:01. (G) 
Differences in ΔMHC between DQB1*03:02 and *03:03, which differ at 57β, and between HLA-DQB1*03:01 and *03:03, which differ at 13β, 26β, and 45β in the 
β1 domain (Supplemental Figure 12B and 13B). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-tailed t test. Error bars represent the SEM (n ≥3).
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those of Gln47α and Cys47α (Figure 5F). Therefore, DQ2.2 and 
DQ9.2, which carry Lys47α, are intrinsically more stable than the 
heterodimers formed by DQA1*03–*06.
In HLA-DQB1*02, *03, and *04, none of the variants were 
associated with ΔMHC (Figure 4C and Supplemental Table 2). 
Non-Asp/Asp57β is responsible for the differences in the ΔMHC 
within DQB1*03, but not the entire DQ2/3/4 that is attributable to 
HLA-DQA1 (Figure 5G).
In both DQ5/6 and DQ2/3/4, the hierarchies in ΔMHC are 
generated mainly through stabilization and destabilization at the 
polymorphic sites that mediate the intersubunit or interdomain 
interactions or the interaction with the peptide main chain. These 
findings demonstrate that the major factor that determines the 
ΔMHC is the intrinsic stability of the MHC protein. Based on these 
and earlier findings, the ΔMHC values in Figure 2A were used as 
indicators of the intrinsic stability of HLA-DQ.
Evolutional divergence at 47α. The extensive variation at the 47α 
stability regulatory site (Supplemental Figure 13A) suggests that 47α 
may have been the target of positive natural selection, as has been 
observed for the peptide-binding sites (74, 75). The variants at 47α 
may have appeared before or at the time of the divergence of the 
HLA-DQA1 sublineages (Figure 6A). To determine whether positive 
selection has been operating at 47α, we compared the number of 
nonsynonymous substitutions per nonsynonymous sites (dn) with 
the number of synonymous substitutions per synonymous sites (ds) 
(Lys vs. Cys and Gln), 52α (His vs. Arg), and 54α (Leu vs. Phe) were 
most strongly associated with ΔMHC (P = 4.4 × 10–11 by 2-tailed t 
test) (Figure 4B and Supplemental Table 2). In the structures of 
DQ2.5 and DQ8.3 (69, 72), 47α is located at the interface of the 
α1 and α2/β2 domains and appears to affect heterodimer stability. 
Arg52α, which does not participate in interdomain interaction, and 
Phe54α, which projects its side chain  toward the outer surface or to 
the β1 domain, does not seem to explain the lower ΔMHC values of 
DQA1*03 and *05 compared with those of DQA1*02.
47α, which encodes Arg, Lys, Gln, and Cys, is the most variable 
site in HLA-DQA1 (Supplemental Figure 13A). Unlike typical MHC 
polymorphisms, 47α is located outside the peptide-binding groove 
and TCR-recognition surface (Figure 5A and Supplemental Figure 
14F). In DQA1*01:02, Arg47α forms extensive H-bonds with the 
α2 domain (70), which may be partially maintained by Lys47α (in 
DQA1*02), but not by Gln47α in DQ8.3 (69, 73) or by Cys47α in 
DQ2.5 (ref. 72 and Figure 5, B–D). The substitution of Cys47α with 
Lys47α in DQ2.5 increased the ΔMHC value by 4.1-fold (from 0.10 to 
0.40) (Figure 5E), accounting for approximately 69% to 86% of the 
ΔMHC of DQ2.2 (ΔMHC = 0.46–0.57). The substitution of Gln47α 
with Lys47α in DQ8.3 increased the ΔMHC value by 2.1-fold (from 
0.09 to 0.18) (Figure 5E), accounting for approximately 39% of 
the ΔMHC of DQ8.2 (DQA1*02:01-DQB1*03:02) (ΔMHC = 0.46). 
Mutagenesis at 47α in the least stable DQA1*06:01 confirmed 
greater stabilizing effects of Lys47α and Arg47α compared with 
Figure 6. Evolutionary diversification of the stability regulatory sites. (A) 
Neighbor-joining tree for HLA-DQA1 showing the amino acid substitutions at 
2α and 47α. (B and C) dn-ds for codons in HLA-DQA1 (14 alleles) (B), and ape 
DQA1 (20 alleles) (C). The x axis indicates the amino acid residue numbers 
starting at 18α and ending at 79α. The y axis indicates the dn-ds at each 
codon, as calculated by the Nei-Gojobori method (124) using SNAP (126) 
(http://www.hiv.lanl.gov). The codons with a positive dn-ds (P < 1 × 10–7, 
calculated for pn and ps) are plotted in orange. (D) Location of the amino 
acid residues that showed a positive dn-ds (P < 1 × 10–7) in both human and 
ape DQA1. See Supplemental Tables 3 and 4 for the association tables.
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synonymous differences per 
synonymous site [ps] and the 
proportion of nonsynonymous 
differences per nonsynony-
mous site [pn]; see Methods). 
The codons for 47α showed 
a dn-ds value that was one of 
the highest in DQA1 (dn-ds = 
0.443, P = 1.63 × 10–11 in human 
DQA1; dn-ds = 0.664, P = 1.43 
× 10–23 in ape DQA1) (Figure 
6, B and C, and Supplemental 
Tables 3 and 4), indicating that 
47α has been subjected to pos-
itive diversifying selection. The codons for 47α in swine DQA1 also 
showed a significantly positive dn-ds value (H. Miyadera, unpub-
lished observations). The other residues that showed significantly 
positive dn-ds values (P < 1.0 × 10–7) in both human and ape DQA1 
were 25α, 34α, 40α, 45α, 48α, 69α, and 76α (Figure 6, B–D, and 
Supplemental Tables 3 and 4). Of these, 25α and 34α participate in 
peptide-binding and protein stability regulation, and 69α and 76α 
for each codon in the DQA1 of human, ape, and other mammals. 
The comparison of dn with ds detects a positive selection operating 
on each codon or gene. Under a null hypothesis of selective neutral-
ity, the dn = ds is expected (ref. 76 and references therein).
In human and ape DQA1, the codons for 69α showed the highest 
dn-ds value (dn-ds = 1.573, P = 5.17 × 10–12 in human DQA1; P value 
calculated by the Wilcoxon signed-rank test for the proportion of 
Figure 7. Association between the 
ΔMHC and genetic risk for T1D. 
(A) Frequencies of DQ haplotypes 
in T1D cases and controls in the 
Swedish (77, 78) and Japanese pop-
ulations (10). See Supplemental 
Table 5 for the association table. 
(B) Frequencies of DQ haplotypes 
of various ΔMHC levels in the 
Swedish (77, 78) and Japanese 
populations (10). Lines indicate the 
boundaries for the ΔMHC less than 
0.2 (yellow) and the ΔMHC greater 
than 0.8 (white). (C) ΔMHC profiles 
for the major DQ haplotypes 
(haplotype frequency >0.03) in 
the European (133) and Japanese 
populations (134). Colors indicate 
the DQ haplotypes that confer risk 
(magenta), protection (blue), or 
neutrality (gray) with regard to T1D 
in the Swedish (77, 78) and Japa-
nese populations (10). (D) Relation-
ship between the ΔMHC and the 
ORs for the major DQ haplotypes 
(haplotype frequency >0.03) in the 
Swedish and Japanese populations. 
The left axis indicates the OR, and 
the right axis indicates the ΔMHC. 
The dashed lines indicate a 95% 
CI for the ORs or standard errors 
for the ΔMHC. T1D risk (magenta), 
protective (blue), and neutral (gray) 
haplotypes. Haplotypes that are 
most strongly associated with 
susceptibility to or protection 
against T1D in each population are 
indicated by bold lines. P values 
indicate the association between 
the rankings in the ΔMHC and the 
ORs (Spearman’s rank test).
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The composition of the DR-DQ haplotypes differs greatly 
between the Swedish and Japanese populations (Figure 7A); how-
ever, the frequency of the DQ haplotypes is similar in the 2 pop-
ulations when the haplotypes are subgrouped by ΔMHC (Figure 
7B). The DQ haplotypes with low ΔMHC values (ΔMHC <0.2) are 
predominant in T1D cases, whereas those with high ΔMHC values 
(ΔMHC >0.8) are present at higher frequencies in controls than in 
T1D cases (Figure 7B). The steep hierarchy in ΔMHC among the 
DQ haplotypes appears to be correlated with the risk and protec-
tion for T1D (Figure 7C and Supplemental Figure 15, A and B).
Indeed, a clear inverse relationship exists between ΔMHC 
and susceptibility to T1D (estimated by the odds ratio [OR]) for 
the majority of DQ haplotypes, including those haplotypes that 
are most predisposing (DQ2.5, DQ8.3, DQ9.3, and DQ4.3) and 
protective (DQ0602, DQ0603, and DQ9.2). In the absence of 
DQ0501 and DQ0503 (in the Swedish and Japanese populations) 
and DRB1*04:06-DQ8.3 (in the Japanese population), which 
encode unstable HLA-DQ proteins and are neutral or protective 
of T1D, the rankings in ΔMHC and in the ORs were inversely asso-
ciated (P = 4.3 × 10–4 [Swedish]; P = 0.03 [Japanese], Spearman’s 
rank correlation test) (Figure 7D). Although the CIs for the ORs 
are large, these data confirm an overall inverse relation between 
ΔMHC and genetic risk for T1D. The protective phenotype of the 
DRB1*04:06-DQ8.3 haplotype may be ascribed to DRB1*04:06 
constitute the peptide-binding pockets. The significant excess of 
dn versus ds at 47α was not due to positive selection operating on 
antigen-binding sites, because the variants at 47α were not in link-
age disequilibrium with the variants at the peptide-binding sites, 
such as 25α and 69α. The signature of positive selection at 47α inde-
pendently of antigen-binding sites suggests that HLA-DQ has been 
evolving in favor of diversification in protein stability, in addition to 
increasing variations in the peptide-binding spectrum.
Autoimmune-susceptible DQ haplotypes encode unstable pro-
teins. We next analyzed the relationship between ΔMHC and 
genetic risk for autoimmunity using the ΔMHC profile (Figure 2A) 
and case-control data for T1D in Swedish (77, 78) and Japanese 
populations (10). T1D is caused by the autoimmune destruction of 
insulin-producing β cells in the pancreas. Both HLA-DR and HLA-
DQ confer a predisposition to T1D. The association of DR-DQ 
haplotypes with T1D has been extensively studied, and the risk 
hierarchy among the haplotypes has been established (59, 79, 80). 
In European and African-American populations, DR3-DQ2.5 and 
DR4-DQ8.3 are the risk haplotypes for T1D (59, 79–81). In the Jap-
anese population, DR9-DQ9.3 and DR4-DQ4.3 are most strongly 
associated with T1D (8–10). DR9-DQ9.3 confers a risk for T1D in 
the Filipino and Korean populations (8, 82, 83). DQ0602 confers 
protection against T1D in Swedes and Japanese, among other pop-
ulations (ref. 79, Figure 7A, and Supplemental Table 5).
Figure 8. Association analyses between the amino acid variants in HLA-DQ and susceptibility to T1D. (A–D) Associations between the amino acid vari-
ants in HLA-DQA1 (A and B) and -DQB1 (C and D) and susceptibility to T1D in the Swedish (A and C) and Japanese populations (B and D). The ORs (circles) 
and the lowest P value (triangle) at each site (χ2 test). ORs and P values for the variants that are distinct between DQ2/3/4 and DQ5/6 are shaded in 
orange. ORs for 2α and 199α in the Swedish population are not presented. See Supplemental Tables 6 and 7 for the association tables.
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the TCR (95). The protein-destabilizing effect of non-Asp57β may 
also contribute to T1D. However, the neutral phenotype of DQ2.2  
(non-Asp57β, ΔMHC = 0.46–0.57) (59, 80) and the susceptible 
phenotypes of DQ9.3 and DQ4.3 (Asp57β, ΔMHC = 0.05–0.12) 
suggest that the low ΔMHC value, rather than non-Asp57β, is indis-
pensable to the shared mechanism of T1D risk across ethnicities.
Except for 57β in the Swedish population, we found that no 
variant in the peptide-binding sites showed an association sig-
nal that was stronger than the signals observed for the sublin-
eage-specific variants (i.e., variants that differ between DQ2/3/4 
and DQ5/6) (Figure 8, A–D). These results indicate that (a) a cer-
tain combination of the peptide-binding variants confers a risk for 
T1D, or (b) the peptide-binding spectrum is not strongly associ-
ated with T1D. The observations that the peptide-binding spec-
tra of DQ2/3/4 partially overlap and are partially unique (96–98) 
permit both mechanisms.
Collectively, the absence of a common association signal for 
T1D in the peptide-binding sites confirms the predisposing effect 
of HLA-DQ protein instability. Among the multiple factors that 
might contribute to T1D risk, instability of HLA-DQ may be one of 
the major components that determines the pathogenic potential of 
each DR-DQ haplotype.
Discussion
To uncover the mechanism of the HLA-autoimmunity association, 
the most logical approach would be to identify the functional vari-
ation(s) among HLA alleles that are correlated with disease risk. 
The present study revealed an inverse association between ΔMHC 
and T1D and confirmed the strong association signals for T1D at 
the protein-destabilizing variants. These results suggest a potential 
causal link between the intrinsic instability of HLA-DQ and T1D.
The HLA-autoimmunity association has been explained for 
decades by the allele-specific presentation of disease-relevant 
self-peptides (referred to as the peptide specificity model) (Figure 
9A). Our study indicates that the intrinsic instability of the MHC 
protein may also be a major functional component of autoimmune 
susceptibility (i.e., the MHC stability model) (Figure 9B). The 2 
mechanisms are not mutually exclusive, and neither mechanism 
alone sufficiently explains the DR-DQ haplotype association with 
T1D. The combination of the 2 parameters might generate the 
high level of allele specificity in the autoimmune disease risk.
The simplest mechanism by which an unstable MHC protein 
might confer autoimmune disease risk would be the contribution 
of MHC protein instability to the incomplete thymic negative selec-
tion. This possibility is consistent with the established concept 
of autoimmunity, in which the formation of an unstable pMHC 
(59, 79, 80). The protective association of DQ0503 may be attrib-
utable to DR14 (84).
Destabilizing variants at 47α confer a predisposition to T1D. 
To address whether the association between ΔMHC and T1D is 
affected by the peptide-binding variants, we analyzed the associa-
tion between each amino acid variant and T1D. In HLA-DQA1, the 
strongest association signals with T1D in the Swedish population 
were detected at 47α (Gln and Cys vs. Arg and Lys) and 52α (Arg vs. 
Ser and His) (OR = 4.33, P = 1.2 × 10–57, χ2 test), which are the vari-
ants that differ between HLA-DQA1*01, *02, and *03-*06 (Figure 
8A and Supplemental Table 6). The association of Arg52α with T1D 
has been noted previously (85, 86), but Arg52α  may not affect the 
stability or peptide binding in the structures of DQ2.5 and DQ8.3 
(69, 72). In the Japanese population, variants at 26α (Ser vs. Thr), 47α 
(Gln vs. Arg and Cys), 50α (Leu vs. Glu and Val), 53α (Arg vs. Lys and 
Gln), 55α (Arg vs. Gly and Del), 76α (Val vs. Leu and Met), 187α (Thr 
vs. Ala), and 215α (Leu vs. Phe), which distinguish HLA-DQA1*03 
from other alleles, were the most strongly associated with T1D 
(OR = 3.79, P = 2.9 × 10–43) (Figure 8B and Supplemental Table 6). The 
2 populations share the risk variant Gln47α. Cys47α is not associated 
with T1D in the Japanese population due to the absence of DQ2.5 
(risk haplotype) and the presence of DQ7.5 (protective haplotype).
Non-Asp57β has been known as a T1D risk variant in Europe-
ans (87, 88) and in murine models (89). As expected from earlier 
studies, variants at 57β were strongly associated with T1D in the 
Swedish population (Ala and Ser vs. Asp and Val, OR = 5.22, P = 
5.3 × 10–76; non-Asp vs. Asp, OR = 5.23, P = 6.1 × 10–68) but not in 
the Japanese population (Figure 8, C and D, and Supplemental 
Table 7). Non-Asp57β may confer a risk for T1D through an altera-
tion in the binding preference for the p9 residue (90–94) and for 
Figure 9. Hypothetical mechanisms of the HLA-autoimmunity asso-
ciation. (A) Peptide specificity model. This model postulates that the 
peptide-binding spectrum of the MHC determines the genetic association 
of HLA with autoimmunity. According to this model, the HLAs that are 
able to present the disease-relevant peptides (magenta) confer a risk for 
autoimmunity. Colors indicate the disease-relevant (magenta) and irrel-
evant peptides (white). (B) MHC stability model. This model postulates 
that intrinsically unstable MHC proteins (magenta), which form unstable 
MHC–self-epitope complexes through presentation of diverse self-pep-
tides and are more likely to form unstable pMHC than intrinsically stable 
MHC, confer a risk for autoimmunity.
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In this study, ΔMHC was used as an indicator of the intrinsic 
stability of the MHC protein. Several lines of direct and indirect 
evidence, including the mutagenesis studies, have confirmed 
that the intrinsic stability of the MHC protein is the major factor 
in determining ΔMHC. In fibroblasts, the stabilization of MHC II 
promotes rapid transport of pMHC into the Golgi apparatus (118), 
and the MHC II proteins that weakly interact with peptides are 
protease sensitive and are degraded in the endosomes (50). In 
B cells, unassembled HLA-DR subunits can be degraded rapidly 
during intracellular transport (119, 120). Presumably, intrinsically 
less stable MHC proteins that are inefficient in both α and β sub-
unit assembly and in the formation of the pMHC may generate a 
substantial amount of unassembled or unfolded subunits that are 
sensitive to proteolysis, resulting in reductions in both the number 
and lifetime of the pMHCs that reach the cell surface. However, 
because ΔMHC is measured by the cell-based assay, the possibility 
that ΔMHC is biased by unknown cellular components cannot be 
completely ruled out.
It should also be noted that the ΔMHC profile, which is mea-
sured in an engineered condition, does not represent the expres-
sion profile of HLA-DQ on professional APCs. As observed in 
B-LCLs, the HLA-DQ alleles that showed low ΔMHC values can 
be expressed at a high level (36), possibly through transcriptional 
upregulation and/or stabilization by high-affinity peptides.
Our study provides new insights into the molecular evolu-
tion of the MHC, which has been explained by diversification of 
the peptide-binding spectrum (ref. 121 and references therein). 
The DQ haplotypes that encode unstable and stable proteins are 
maintained at a high frequency in a variety of populations (allele-
frequencies.net; ref. 122), indicating that the alleles encoding 
unstable HLA-DQ heterodimers are not selectively disadvanta-
geous. Presumably, both the stable and unstable MHC may have 
functional advantages against important pathogens. The stability 
of HLA-DR may also be diverse (123); however, the scale of varia-
tion may be limited by the monomorphic nature of HLA-DRA.
Collectively, our study reveals an additional layer of func-
tional hierarchy among the HLA alleles that has been generated 
through evolution and is associated with autoimmunity. These 
findings complement and extend the existing model of the 
HLA-autoimmunity association and suggest a mechanistic basis 
of autoimmune susceptibility.
Methods
Measurement of ΔMHC. Full-length cDNAs for HLA-DQA1 and-
DQB1 were cloned from HLA-typed cell lines or peripheral blood 
samples from healthy individuals. The cDNAs were inserted into 
the retroviral vectors pMXs-puro or pMXs-IG (52) with an EcoRI 
site and a Kozak sequence in the 5′ terminus and a Strep-tag II (IBA 
GmbH) and a His-tag in the 3′ terminus of HLA-DQA1 and -DQB1, 
respectively. The first nucleotide of the second amino acid of HLA-
DQA1 and -DQB1 was changed to guanine to introduce a Kozak 
sequence. The HLA-DQA1-Strep-tag II and HLA-DQB1-His-tag were 
inserted into the pMXs-puro and pMXs-IG vectors, respectively, 
using EcoRI and NotI sites. To generate the retroviruses contain-
ing pMXs-puro/DQB1 and pMXs-IG/DQA1, approximately 0.5–1 × 
106 PLAT-E cells (53) were transfected with 1.5 μg plasmid and 4.5 
μl Fu-GENE reagent (Roche Diagnostics), according to the manu-
by low-affinity peptides permits thymic escape of self-reactive 
T cells (99, 100). Upon weak self-epitope presentation, intrinsi-
cally unstable MHC may form MHC–self-epitope complexes in the 
low-stability range and confer a risk for autoimmunity. The ability 
of intrinsically unstable MHC to form unstable pMHC with diverse 
self-epitopes, including the promiscuous binders, may explain the 
association of T1D risk DR-DQ haplotypes with a variety of autoim-
mune disorders (Table 1), as well as the involvement of promiscu-
ous self-epitopes in allele-specific disease pathogenesis.
The intrinsically unstable MHC protein may be expressed 
either at a basal level or maximum level depending on the avail-
ability of high-affinity peptides and accessory molecules. The 
intrinsically unstable MHC protein is also expected to preferen-
tially present high-affinity peptides on the cell surface. In contrast, 
intrinsically stable MHC may be expressed relatively constantly on 
the cell surface and present the peptides with wider affinity ranges. 
The potential variation in the expression patterns of each MHC 
type might affect the outcomes of thymic selection, peripheral 
activation, and subset development of T cells (101–105), processes 
that are controlled by cell-surface MHC density. The actual mech-
anism that links MHC instability to autoimmunity should involve 
diverse immunological processes and could be highly complex.
The ΔMHC profile provides a clue for dissecting the mech-
anism of the DQ haplotype association with T1D risk. The high 
risk for T1D of DQ2.5/DQ8.3 heterozygotes (58, 59, 79, 80) may 
be ascribed to the instability of DQA1*05-DQB1*03:02 (DQ8.5) 
(ΔMHC = 0.05) (Figure 7C and Supplemental Figure 15, A and B) 
and its unique peptide-binding spectrum (106, 107).
DQ0602 and DQ9.2 may confer protective effects through 
abundant or sustained MHC expression. The high stability of 
DQ0602 and its ability to bind diabetogenic self-epitopes (30–32) 
are compatible with the proposed mechanisms of protection, such 
as the thymic deletion of self-reactive T cells (108) and the “affin-
ity model” or “determinant capture” (106, 109, 110). The protec-
tive associations of DRB1*15:01-DQB1*06:02 with T1D, autoim-
mune polyglandular syndrome (APS) types II and III, and selective 
IgA deficiency (Table 1) suggest a shared mechanism of protection 
among these disorders.
The neutral and protective phenotypes of DQ0501, DQ0503, 
DQ7.3, and DQ7.5, which encode unstable HLA-DQ proteins (Fig-
ure 7D and Supplemental Figure 15B), are not explained by the 
ΔMHC value. As established for the DRB1*04-DQ8.3 haplotypes 
(10, 59, 79–81), the predisposing and protective phenotypes of 
DR-DQ haplotypes can be largely influenced by the DR allele. The 
instability of HLA-DQ could be the condition that permits the 
linked DR to exert pathogenic or protective effects. The increased 
risk for T1D of DQ8.3/DQ0501 and DQ8.3/DQ0604 heterozy-
gotes (79, 80, 111, 112) (DR4/DR13 in the Japanese population; 
refs. 8–10), which do not generate trans DQ heterodimers (Figure 
2A), also remains difficult to explain by the existing hypothesis.
The dependency of MHC II on the invariant chain, CLIP, and 
HLA-DM are proposed as the risk factors for T1D (113–117). The 
affinity of HLA-DQ with CLIP81–107 appears to be variable among 
the alleles (Figure 3D). The dependency of HLA-DQ on HLA-DM 
may also be variable due to polymorphisms at the 47α–56α seg-
ment (117). It will be intriguing to speculate how these interrelated 
parameters and their combinations might affect T1D risk.
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GmbH) and His-tag at the 3′ terminus of HLA-DQA1 and -DQB1, 
respectively. The expression plasmids were cotransfected with 
pCoBlast (Invitrogen) into the Drosophila melanogaster Schneider 
cell line (S2) via calcium phosphate transfection (Invitrogen) or lipo-
fection using Effectene (QIAGEN), according to the manufacturer’s 
instructions. Stable polyclonal cells were obtained in the presence 
of blasticidin (25 μg/ml). For each HLA-DQA1 and -DQB1 allelic 
pair, stable cells were obtained from more than 3 independent trans-
fections. The expression of HLA-DQ proteins was induced with 0.5 
mM CuSO4 for 48 hours and measured by flow cytometry (EPICS-
XL; Beckman Coulter) with an anti–HLA II β mAb (WR18, FITC 
conjugate) (MorphoSys AG) or an isotype control (mouse IgG2a–
FITC) (Beckman Coulter). 3′ Rapid amplification of cDNA ends (3′-
RACE) was performed with the 3′-Full RACE Core Set (Takara Bio) 
using total RNA (1 μg) from the stable S2 cells as a template. Total 
RNA was primed for reverse transcription at 42°C with the Oligo 
dT-3 Sites Adaptor Primer (Takara Bio). 3′-RACE PCR was per-
formed according to the manufacturer’s instructions. Specifically, 
the internal primers for HLA-DQA1 (p-50: 5′-ACTCTACCGCTGC-
TACCAATG-3′) and HLA-DQB1 (p-48: 5′-ACGGTGTGCAGACA-
CAACTAC-3′) were used as the 5′ primers, and the Oligo dT-3 Sites 
Adaptor Primer was used as the 3′ primer. The Drosophila ribosomal 
protein rp49 was amplified as a positive control with the primers 
p-266 (5′-ATGACCATCCGCCCAGCATAC-3′) and p-267 (5′-TGT-
GTATTCCGACCAGGTTAC-3′). For the purification of HLA-DQ 
proteins and Western blotting, the stably transfected S2 cells were 
harvested 48 hours after induction and stored at –80°C. The cells 
were thawed on ice and lysed in 30 mM sodium phosphate buffer 
(pH 8.0, 150 mM NaCl, 0.5% NP-40) in the presence of a protease 
inhibitor cocktail (Sigma-Aldrich) and Benzonase Nuclease (EMD 
Millipore, Merck KGaA) for 1 hour at 4°C. The lysate was centrifuged 
at 2,000 g for 10 minutes at 4°C, and the supernatant was subjected 
to purification. Purification by Strep-tag II and His-tag was per-
formed with a Strep-Tactin Spin Column (IBA GmbH) and MagEx-
tractor (Toyobo Co., Ltd.), respectively, according to the manufac-
turers’ instructions. For Western blotting, the elution fractions were 
subjected to denaturation and boiling in the presence of SDS (2%) 
and reducing agents. Strep-Tactin-AP (IBA GmbH) and anti-His6 
mAb-HRP (Roche Diagnostics) were used for the detection of DQα 
and DQβ, respectively.
Evolutionary analysis. The dn-ds for each codon was calculated 
in a pairwise manner by the Nei-Gojobori method (124) with Jukes-
Cantor correction (125) using SNAP (126) (http://www.hiv.lanl.gov). 
The amino acids 18α–79α of the DQA1 for humans (HLA-DQA1, 14 
alleles) and apes (Gogo-DQA1 [Gorilla gorilla], Patr-DQA1 [Pan troglo-
dytes], Hyla-DQA1 [Hylobates lar], and Popy-DQA1 [Pongo pygmaeus], 
20 alleles), which represent all of the alleles that are registered in 
the IMGT/HLA and IMGT/IPD databases (EMBL-EBI) (127–130) 
and which were nonredundant in the 18α–79α region (i.e., at least 1 
codon was different from the others), were used for the analyses. The 
codons with a deletion or insertion (55α and 56α in the human and 
ape DQA1) were excluded from the analysis. For the sequence pairs 
with codons encoding Met or Trp (48α, 66α, and 76α in human and 
ape DQA1), the ps was assumed to be 0 and was used to calculate 
the ds. For sequence pairs showing a ps greater than or equal to 0.75 
(32α, 36α, 60α, 71α, and 75α in human and ape DQA1), the ds was 
not calculated (at these codons, the ps was greater than the pn, and 
facturer’s instructions. HLA-DQB1–stable cells were established 
through the transduction of NIH3T3 cells with a retrovirus contain-
ing pMXs-puro/DQB1 and selection with puromycin (6 μg/ml). To 
measure ΔMHC, the HLA-DQB1–stable cells were seeded at approx-
imately 2 × 105 cells per well in a 12- or 24-well plate and cultured 
overnight. The cells were transduced with a retrovirus containing 
pMXs-IG/DQA1 using 5–60 μl PLAT-E medium. Forty-eight hours 
after transduction, GFP and cell-surface MHC (in GFP-positive 
cells) levels were measured by flow cytometry (EPICS-XL; Beckman 
Coulter) using anti–HLA II β mAb (WR18) (65) (MorphoSys AG) or 
isotype control (mouse IgG2a [6H3]; Medical & Biological Laborato-
ries Co. Ltd.) with phycoerythrin-conjugated anti-mouse IgG (Rock-
land Immunochemicals or Southern Biotechnology Associates Inc.). 
The MFI (GFP) was defined as the MFI for GFP-positive cells minus 
MFI for GFP-negative cells. The MFI (MHC) was defined as the MFI 
for anti–HLA II β [WR18] minus the MFI for the isotype control of 
the GFP-positive cells (Supplemental Figure 3A). The MFI (GFP) 
and MFI (MHC) were plotted to calculate the increase in the MHC 
relative to GFP (ΔMHC) (Figure 1D and Supplemental Figure 3B). To 
minimize interassay variation, the ΔMHC for each DQ heterodimer 
was normalized with the ΔMHC value of DQ0602, which was mea-
sured on the same day (Figure 1D and Supplemental Figure 4, A and 
B). The lower detection threshold of ΔMHC was set at 0.005 (after 
normalization to DQ0602). The assay was performed more than 
3 times for each HLA-DQA1 and -DQB1 allelic pair. Site-directed 
mutagenesis was performed with QuikChange II (Agilent Technol-
ogies), according to the manufacturer’s instructions. The following 
anti-HLA mAbs were purchased: BL-IA/6 (Santa Cruz Biotechnol-
ogy Inc.) and TDR31.1 (Ancell Corporation). The mAb IVA12 was a 
gift of S. Kawai (Wakunaga Pharmaceutical Co.). The NIH3T3 cell 
line was obtained from the RIKEN Cell Bank.
The HLA-DQB1-peptide fusion construct was designed as 
described in Kozono et al. (66), with modification. Briefly, the 
sequences for insulin B1–15, insulin B9–23, CLIP81–107, and an artificial 
GGS peptide (GGSGGSGGSGGS) were inserted between the sig-
nal sequence of HLA-DQB1*06:02 and the mature protein region of 
HLA-DQB1 via linkers (SGG and GGGGSIEGRGGGGSGSA at the 
N and C termini of the peptide, respectively). The fragments that 
encode the signal sequence and the peptide sequences were syn-
thesized as double-stranded DNA and were ligated to the mature 
DQB1 sequence using the AccIII site. For the DQB1-peptide fusion 
constructs, ΔMHC was measured in HLA-DQA1–stable cells.
To establish NIH3T3 cells that stably express the human invari-
ant chain, the full-length cDNA for the invariant chain (isoform b) 
was cloned from the B-LCL of the healthy individual and was inserted 
into pMXs-neo using EcoRI and Not I at the 5′ and 3′ termini of the 
invariant chain, respectively. NIH3T3 cells were transduced with the 
pMXs-neo/invariant chain and were selected with G418 (2 mg/ml) for 
2 weeks. The invariant chain–stable cells were then transduced with 
pMXs-puro/HLA-DQA1 and were selected with puromycin (6 μg/ml). 
Expression of the invariant chain was detected with anti–invariant 
chain mAb (LN2) (BioLegend). Intracellular staining was performed 
using the FIX & PERM Cell Fixation and Cell Permeabilization Kit 
(Invitrogen), according to the manufacturer’s instructions.
Expression of HLA-DQ protein in insect cells. Full-length cDNAs 
for HLA-DQA1 and -DQB1 were inserted into pMT-V5/His (Invitro-
gen) with a Kozak sequence at the 5′ terminus and a Strep-tag II (IBA 
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a 2-tailed t test. Differences between ps and pn and between ds and dn 
were analyzed by the Wilcoxon signed-rank test. Associations between 
the DQ haplotype frequency and susceptibility to T1D were analyzed 
by the χ2 test with Bonferroni’s correction. Spearman’s rank test was 
used to evaluate associations between the ranking in the ΔMHC and 
ORs. A χ2 test test was used to analyze associations between the amino 
acid variants and genetic risk for T1D. A P value of less than 0.05 was 
considered statistically significant.
Study approval. The use of cDNAs and cell lines from healthy indi-
viduals was approved by the ethics committee of the Graduate School 
of Medicine, The University of Tokyo, and written informed consent 
was obtained from all participants.
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there were no codons with a pn ≥0.75) (Supplemental Tables 3 and 4). 
To assess the possibility of positive selection (i.e., diversifying selec-
tion), the differences between the ps and pn as well as between the 
ds and dn were statistically tested for each codon using the Wilcoxon 
signed-rank test. A neighbor-joining phylogenetic tree was con-
structed for the nucleotide sequences of exon 2 of the HLA-DQA1 
alleles using the alleles with frequencies greater than 0.02 in world-
wide populations (131). Molecular Evolutionary Genetics Analysis 
(MEGA) version 4 software (132) was used for the analysis.
Association analysis between the ΔMHC and genetic risk for T1D. 
The case-control data for T1D in the Swedish population (77) were 
collected and genotyped by the T1D component of the 13th Interna-
tional Histocompatibility Workshop (78) and were deposited in the 
dbMHC database (http://www.ncbi.nlm.nih.gov/projects/gv/mhc/). 
For the Japanese population, published case-control data (10), which 
were collected and genotyped by the Committee on T1D of the Japa-
nese Diabetes Society, were used for the analysis. All of the T1D sub-
types in the Japanese population (acute, fulminant, and slowly pro-
gressive) (10) were combined. The HLA-DQA1 alleles were manually 
estimated from the DRB1-DQB1 haplotype data based on the DRB1-
DQA1-DQB1 haplotype frequency in the general European-American 
(133) and Japanese (134) populations. In the Japanese population, all 
of the DRB1*08:02-DQB1*03:02 haplotypes were assumed to carry 
HLA-DQA1*03. The rare DRB1-DQB1 haplotypes and DRB1-DQB1 
haplotypes that are linked to more than 2 HLA-DQA1 alleles were 
excluded from the analysis. Closely related alleles, such as HLA-
DQA1*01:04 and *01:05; HLA-DQA1*05:01, *05:03, and *05:05; 
and HLA-DQB1*04:01 and *04:02, were assumed to have identical 
ΔMHC values. Because not all of the HLA-DQA1*03 and -DQB1*02 
alleles were genotyped at a 4-digit resolution in the case-control 
data, the ΔMHC values of DQA1*03 and of DQB1*02 were assumed 
to be the average of the ΔMHC values for DQA1*03:01, *03:02, and 
*03:03, and of DQB1*02:01 and *02:02, respectively, and were 
used for the association analyses. For the analysis of the association 
between the amino acid variants and genetic risk for T1D, the vari-
ants at 160α, which differ between HLA-DQA1*03:01 and *03:03, 
and at 135β, which differ between HLA-DQB1*02:01 and *02:02, 
were excluded from the analysis.
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